The landscape of nanoparticle-based siRNA delivery and therapeutic development
Molecular Therapy · 2024-02 · 32 (2) · 284-312
DOI: 10.1016/j.ymthe.2024.01.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2024-02. Verfasst von Muhammad Moazzam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering and Science, University of Greenwich, Medway Campus, Chatham Maritime, Kent ME4 4TB, UK. Hauptthemen laut MEDLINE: Polymers, Nanoparticles, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 245-mal zitiert (Crossref) und nennt 287 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Nova Program, Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park, National Key Research and Development Program of China.
Abstract (Originalsprache)
Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and vutrisiran. Besides, siRNA delivery to the target site without toxicity is a big challenge for researchers, and naked-siRNA delivery possesses several challenges, including membrane impermeability, enzymatic degradation, mononuclear phagocyte system (MPS) entrapment, fast renal excretion, endosomal escape, and off-target effects. The siRNA therapeutics can silence any disease-specific gene, but their intracellular and extracellular barriers limit their clinical applications. For this purpose, several modifications have been employed to siRNA for better transfection efficiency. Still, there is a quest for better delivery systems for siRNA delivery to the target site. In recent years, nanoparticles have shown promising results in siRNA delivery with minimum toxicity and off-target effects. Patisiran is a lipid nanoparticle (LNP)-based siRNA formulation for treating hereditary transthyretin-mediated amyloidosis that ultimately warrants the use of nanoparticles from different classes, especially lipid-based nanoparticles. These nanoparticles may belong to different categories, including lipid-based, polymer-based, and inorganic nanoparticles. This review briefly discusses the lipid, polymer, and inorganic nanoparticles and their sub-types for siRNA delivery. Finally, several clinical trials related to siRNA therapeutics are addressed, followed by the future prospects and conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Engineering and Science, University of Greenwich, Medway Campus, Chatham Maritime, Kent ME4 4TB, UK.
- School of Life Science, Advanced Research Institute of Multidisciplinary Science, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmac…
- Department of Immunology, School of Basic Medical Sciences, Key Laboratory of Medical Immunology of Ministry of Health, Peking University, Beijing 100191, China. Electronic address: xiaotong_pharm@pku.edu.cn.
- Department of Hepatobiliary Surgery, China-Japan Friendship Hospital, Beijing 100029, China. Electronic address: huangjia@zryhyy.com.cn.
Förderung
- Beijing Nova Program
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024). The landscape of nanoparticle-based siRNA delivery and therapeutic development. Molecular Therapy, 32(2), 284-312. https://doi.org/10.1016/j.ymthe.2024.01.005
Vancouver
Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Molecular Therapy. 2024;32(2):284-312. doi:10.1016/j.ymthe.2024.01.005
BibTeX
@article{Moazzam2024,
author = {Moazzam, Muhammad and Zhang, Mengjie and Hussain, Abid and Yu, Xiaotong and Huang, Jia and Huang, Yuanyu},
title = {The landscape of nanoparticle-based siRNA delivery and therapeutic development},
journal = {Molecular Therapy},
year = {2024},
volume = {32},
number = {2},
pages = {284--312},
doi = {10.1016/j.ymthe.2024.01.005}
}
EUVIMED